Sonidegib is a potent oral SMO inhibitor, which showed efficacy in patients with solid tumors [68] and was evaluated in a phase II (ClinicalTrials.gov: NCT01125800, 26 May 2020) and a phase III trial (ClinicalTrials.gov: NCT01708174, 26 May 2020) in pediatric and adult patients with medulloblastoma [69]. The gene discussed is SMO; the disease is medulloblastoma.